期刊文献+

白介素25、33在慢性荨麻疹患者外周血中的表达及意义 被引量:31

Expressions of interleukin-25 and interleukin-33 in peripheral blood of patients with chronic urticaria and their significance
原文传递
导出
摘要 目的探讨慢性荨麻疹患者外周血中自介素(IL)-25、IL-33的表达及意义。方法慢性荨麻疹患者93例,健康人对照30例。慢性荨麻疹组口服氯雷他定治疗4周。采用酶联免疫吸附试验(ELISA)检测外周血IL-25、IL-33水平,分析慢性荨麻疹患者治疗前IL-25、IL-33水平与病情严重程度的相关性。结果慢性荨麻疹患者治疗前IL-25、IL-33水平分别为(139.86±28.48)、(91.95±21.88)ng/L,健康对照组分别为(114.41±34.00)、(79.80±30.72)ng/L,慢性荨麻疹患者IL-25、IL-33水平较健康对照组显著升高(P〈0.01和〈0.05),且与患者病情呈正相关(r分别为0.38和0.42,均P〈0.01)。慢性荨麻疹患者口服氯雷他定治疗4周后,有效率为81.72%,患者IL-25表达水平为(116.48±21.94)ng/L,较治疗前明显降低(P〈0.01),与健康对照组相比差异无统计学意义(P〉0.05);IL-33表达水平为(90.88±20.62)ng/L,较治疗前差异无统计学意义(P〉0.05)。结论IL-25、IL-33在慢性荨麻疹患者外周血中表达水平升高,并与病情严重程度呈正相关。 Objective To detect the expression levels of interleukin (IL)-25 and IL-33 in peripheral blood of patients with chronic urticaria. Methods Ninety-three patients with chronic urticaria were included in this study along with 30 healthy individuals. All the patients were treated with loratadine for four weeks. Blood samples were collected from the healthy controls and patients before and after the four-week treatment. Enzyme-linked immunosorbent assay (ELISA) was performed to detect the serum levels of IL-25 and IL-33. The relationship between the expression levels of the two cytokines and urticaria severity was analyzed. Results The serum levels of IL-25 and IL-33 in the patients before treatment were significantly higher than those in the healthy controls (IL- 25, 139.86 ± 28.48 vs. 114.41 ± 34.00 ng/L, P 〈 0.01; IL-33, 91.95 ± 21.88 vs. 79.80 ± 30.72 ng/L, P 〈 0.05), and positively correlated with the severity of urticaria (r = 0.38, 0.42, respectively, both P 〈 0.01 ). After four weeks of treatment, clinical improvement was observed in 81.72% of these patients with a significant decrease in the serum IL-25 level (116.48 ± 21.94 vs. 139.86 ± 28.48 ng/L, P 〈 0.01 ), but no obvious changes in the serum IL-33 level (90.88 ± 20.62 vs. 91.95 ± 21.88 ng/L, P 〉 0.05) compared with those before treatment. Conclusions The expressions of IL-25 and IL-33 are elevated in peripheral blood of patients with chronic urticaria, and positively correlated with the severity of urticaria.
出处 《中华皮肤科杂志》 CAS CSCD 北大核心 2014年第4期284-286,共3页 Chinese Journal of Dermatology
关键词 荨麻疹 白细胞介素33 白细胞介素25 氯雷他定 Urticaria Interleukin-25 Interleukin-33 Loratadine
  • 相关文献

参考文献12

  • 1Licona-Liman P, Kim LK, Palm NW, et al. TH2, allergy and group 2 innate lymphoid cells [J]. Nat Immunol, 2013, 14(6): 536-542.
  • 2Saadoun D, Terrier B, Cacoub P. Interleukin-25: key regulator of inflammatory and autoimmune diseases [J]. Curt Pharm Des, 2011, 17(34): 3781-3785.
  • 3Park CO, Noh S, Jin S, et al. Insight into newly discovered innate immune modulation in atopic dermatitis[J]. Exp Dermatol, 2013, 22( 1 ):6-9.
  • 4Palmer G, Gabay C. Interleukin-33 biology with potential insights into human diseases[J]. Nat Rev Rheumatol, 2011, 7(6): 321-329.
  • 5刘玲玲,朱学骏,姜薇,陈喜雪,李明,彭振辉,郭在培,李福秋.咪唑斯汀治疗慢性荨麻疹的随机双盲研究[J].中华皮肤科杂志,2003,36(6):306-309. 被引量:149
  • 6Hvid M, Vestergaard C, Kemp K, et al. IL-25 in atopie dermatitis: a possible link between inflammation and skin barrier dysfunction? [J]. J Invest Dermatol, 2011, 131 (1): 150-157.
  • 7Gregory LG, Jones CP, Walker SA, et al. IL-25 drives remodelling in allergic airways disease induced by house dust mite [J]. Thorax, 2013, 68( 1 ): 82-90.
  • 8Ferrer M, Kaplan AP. Chronic urticaria: what is new, where are we headed[J]. Allergol Immunopathol (Madr), 2007, 35(2): 57-61.
  • 9Wong CK, Li PW, Lam CW. Intracellular JNK, p38 MAPK and NF-kappaB regulate IL-25 induced release of cytokines and ehemokines from costimulated T helper lymphoeytes[ J ]. Immunol Lett, 2007, 112(2): 82-91.
  • 10Moussion C, Ortega N, Girard JP. The IL-l-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial ceils and epithelial cells in vivo: a novel "alarmin'? [J/OL]. PLoS One, 2008, 3(10): e3331 [2013-03-10]. http://www.ncbi.nlm.nih.gov/ pubmed/18836528.

二级参考文献7

  • 1张宏誉,李宏,岳凤敏,王良录,方权,王瑞琦,秦万章,李明,金岚,秦立模,吴惠俐.咪唑斯汀治疗慢性特发性荨麻疹的多中心随机平行组对照的临床试验报告[J].中华微生物学和免疫学杂志,2001,21(S2):61-64. 被引量:11
  • 2Pichat P;Angel I;Arbilla S.Anti-inflammatory properties of mizolastine after oral administration on arachidonic acid-induced cutaneous reaction in the rat,1998(01).
  • 3Benavides J;Schoemaker H;Dana C.In vivo and in vitro interaction of the novel selective histamine H1 receptor antagonist mizolastine with H1 receptors in the rodent,1995.
  • 4Dubertr;Murrieta Aguttes M;Tonet J.Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria:results of the MILOR Study[J],1999.
  • 5Sabbah A;Daele J;Wade AG.Comparison of the efficacy,safety,and onset of action of mizolastine,cetirizine,and placebo in the management of seasonal allergic rhinoconjunctivitis.MIZOCET Study Group[J],1999.
  • 6Leynadier F;Duarte-Risselin C;Murrieta M.Comparative therapeutic effect and safety of mizolastine and loratadine in chronic idiopathic urticaria URTILOR study group,2000.
  • 7朱大勋.咪唑斯汀和四种常用H_1受体阻滞剂的实验抗组胺强度比较[J].中华皮肤科杂志,2001,34(3):219-220. 被引量:36

共引文献148

同被引文献214

引证文献31

二级引证文献183

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部